The TLR7/8 Agonist R848 Remodels Tumor and Host Responses to Promote Survival in Pancreatic Cancer

Nature Communications - United Kingdom
doi 10.1038/s41467-019-12657-w
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Intratumoral Immunotherapy With the TLR7/8 Agonist 3m-052

Journal for ImmunoTherapy of Cancer
OncologyMolecular MedicinePharmacologyCancer ResearchAllergyImmunology
2013English

Correlation of Tumor Size and Survival in Pancreatic Cancer

Journal of Gastrointestinal Oncology
OncologyGastroenterology
2018English

Orchestrating the Tumor Microenvironment to Improve Survival for Patients With Pancreatic Cancer

Cancer Journal
Cancer ResearchOncology
2015English

CXCL8/IL-8 and CXCL12/SDF-1α Co-Operatively Promote Invasiveness and Angiogenesis in Pancreatic Cancer

International Journal of Cancer
Cancer ResearchOncology
2009English

The TLR7/8/9 Antagonist IMO-8503 Inhibits Cancer-Induced Cachexia

Cancer Research
Cancer ResearchOncology
2018English

Multiagent Neoadjuvant Chemotherapy and Tumor Response Are Associated With Improved Survival in Pancreatic Cancer

HPB
HepatologyGastroenterology
2019English

The TLR7 Agonist Imiquimod as an Adjuvant for Radiotherapy-Elicited in Situ Vaccination Against Breast Cancer

OncoImmunology
OncologyAllergyImmunology
2013English

GITR Agonist Enhances Vaccination Responses in Lung Cancer

OncoImmunology
OncologyAllergyImmunology
2015English

Crosstalk Between Mast Cells and Pancreatic Cancer Cells Contributes to Pancreatic Tumor Progression

Clinical Cancer Research
Cancer ResearchOncology
2010English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy